2.2.0.7 true Collaboration Agreements (Details) (USD $) 0614 - Disclosure - Collaboration Agreements (Details) true false false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ false 2 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ false 3 USD true false false false Development [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_DevelopmentMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false Array BioPharma Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyOneMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 4 USD true false false false Development [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_DevelopmentMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false PTC Therapeutics, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyTwoMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 5 USD true false false false Development [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_DevelopmentMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false Acceleron Pharma [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyThreeMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 6 USD true false false false Discovery Stage Programs [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_DiscoveryStageProgramsMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false Acceleron Pharma [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyThreeMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 7 USD true false false false Commercial [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_CommercialMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false Array BioPharma Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyOneMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 8 USD true false false false Commercial [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_CommercialMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false Cabrellis Pharmaceuticals Corp. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFourMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 9 USD true false false false Future GlobeImmune Programs [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_FutureGlobeImmuneProgramsMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 10 USD true false false false GI-6200, GI-3000 and GI-10000 [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_GI6200GI3000AndGI10000Member celg_CollaborationAgreementsTransactionsAxis explicitMember false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 11 USD true false false false GI-4000 [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_GI4000Member celg_CollaborationAgreementsTransactionsAxis explicitMember false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 12 USD true false false false First E.U. Approval [Member] celg_CollaborationAgreementsTransactionsAxis xbrldi http://xbrl.org/2006/xbrldi celg_FirstEUApprovalMember celg_CollaborationAgreementsTransactionsAxis explicitMember false false Cabrellis Pharmaceuticals Corp. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFourMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 13 USD true false false false Novartis Agreement [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanySixMember dei_LegalEntityAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 14 USD true false false false Array BioPharma Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyOneMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 15 USD true false false false Array BioPharma Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyOneMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 16 true false false false Array BioPharma Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyOneMember dei_LegalEntityAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 false 17 USD true false false false PTC Therapeutics, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyTwoMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 18 USD true false false false PTC Therapeutics, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyTwoMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 19 true false false false PTC Therapeutics, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyTwoMember dei_LegalEntityAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 false 20 USD true false false false Acceleron Pharma [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyThreeMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 21 USD true false false false Acceleron Pharma [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyThreeMember dei_LegalEntityAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 22 USD true false false false Cabrellis Pharmaceuticals Corp. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFourMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ false 23 USD true false false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 24 true false false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 false 25 USD true false false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ false 26 USD true false false false GlobeImmune, Inc. [Member] dei_LegalEntityAxis xbrldi http://xbrl.org/2006/xbrldi celg_CollaborationAgreementsCompanyFiveMember dei_LegalEntityAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ 5 Collaboration Agreements (Textuals) [Abstract] 3 celg_CollaborationAgreementsTextualsAbstract celg false na duration Collaboration Agreements Textuals. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:stringItemType string Collaboration Agreements Textuals. false 6 Potential milestone payment receipts 4 celg_PotentialMilestonePaymentReceipts celg false credit duration Maximum upfront and regulatory achievement amount received under the Licenses Agreement. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 true true false false 100000000 100000000 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Maximum upfront and regulatory achievement amount received under the Licenses Agreement. No authoritative reference available. false 7 Milestone payments received 4 celg_MilestonePaymentsReceived celg false credit duration Milestone payments received. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false true false false 55000000 55000000 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Milestone payments received. No authoritative reference available. false 8 Royalty rate 4 celg_MinimumRoyaltyRate celg false na duration Minimum percentage royality received from sale of Novartis' FOCALIN XR and RITALIN family of ADHD-related products. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false true false false 0.3 0.3 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:pureItemType pure Minimum percentage royality received from sale of Novartis' FOCALIN XR and RITALIN family of ADHD-related products. No authoritative reference available. false 9 Royalty rate 4 celg_MaximumRoyaltyRate celg false na duration Maximum percentage royality received from sale of products. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false true false false 0.35 0.35 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:pureItemType pure Maximum percentage royality received from sale of products. No authoritative reference available. false 10 Upfront payments made 4 us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross us-gaap true debit duration No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false true false false 40000000 40000000 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false true false false 20000000 20000000 true false false 19 false false false false 0 0 true false false 20 false true false false 50000000 50000000 true false false 21 false false false false 0 0 true false false 22 false true false false 12500000 12500000 true false false 23 false true false false 30000000 30000000 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 68 -Paragraph 14 -Footnote 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 68 -Paragraph 14 -Subparagraph b false 11 Potential milestone payments 4 celg_MilestonePayments celg false credit duration Milestone payments. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false true false false 200000000 200000000 true false false 4 false true false false 129000000 129000000 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false true false false 300000000 300000000 true false false 8 false false false false 0 0 true false false 9 false true false false 161000000 161000000 true false false 10 false true false false 145000000 145000000 true false false 11 false true false false 230000000 230000000 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Milestone payments. No authoritative reference available. false 12 Potential payment obligation reduction 4 celg_MaximumPaymentObligationsIfAgreementTerminatedForMaterialBreach celg false na duration Maximum payment obligations, if the agreement terminated for a material breach. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false true false false 0.5 0.5 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure Maximum payment obligations, if the agreement terminated for a material breach. No authoritative reference available. false 13 Equity investment 4 celg_AdditionalInvestmentInConvertiblePreferredStock celg false debit duration Additional Investment in Series G Convertible Preferred Stock of PTC. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false true false false 1500000 1500000 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Additional Investment in Series G Convertible Preferred Stock of PTC. No authoritative reference available. false 14 Potential reduction in future royalties payments, minimum 4 celg_MinimumReductionInFutureRoyaltiesPayableByCompanyUnderMaterialBreachOfAgreement celg false na duration Minimum reduction in future royalties payable by the Company under material breach of agreement. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false true false false 0.5 0.5 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure Minimum reduction in future royalties payable by the Company under material breach of agreement. No authoritative reference available. false 15 Potential reduction in future royalties payments, maximum 4 celg_MaximumReductionInFutureRoyaltiesPayableByCompanyUnderMaterialBreachOfAgreement celg false na duration Maximum reduction in future royalties payable by the Company under material breach of agreement. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false true false false 0.7 0.7 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure Maximum reduction in future royalties payable by the Company under material breach of agreement. No authoritative reference available. false 16 Equity investment 4 us-gaap_OtherLongTermInvestments us-gaap true debit instant No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 5000000 5000000 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false true false false 7000000 7000000 true false false 22 false false false false 0 0 true false false 23 false true false false 10000000 10000000 true false false 24 false false false false 0 0 true false false 25 false true false false 100000 100000 true false false 26 false true false false 3000000 3000000 true false false xbrli:monetaryItemType monetary Other noncurrent investments not otherwise specified in the taxonomy, not including investments in marketable securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 12 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph f -Article 7 false 17 Potential milestone payments 4 celg_EligibleToReceiveMaximumDevelopmentRegulatoryApprovalAndSalesBasedMilestonesForAce011Program celg false credit duration Eligible To Receive Maximum Development Regulatory Approval And Sales Based . false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false true false false 510000000 510000000 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Eligible To Receive Maximum Development Regulatory Approval And Sales Based . No authoritative reference available. false 18 Potential milestone payments 4 celg_EligibleToReceiveMaximumDevelopmentRegulatoryApprovalAndSalesBasedMilestonesForEachOfThreeDiscoveryStagePrograms celg false credit duration Eligible To Receive Maximum Development Regulatory Approval And Sales Based Milestones For Each Of Three Discovery Stage. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false true false false 437000000 437000000 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Eligible To Receive Maximum Development Regulatory Approval And Sales Based Milestones For Each Of Three Discovery Stage. No authoritative reference available. false 19 Potential reduction in royalty payments 4 celg_PaymentObligationsUnderAgreementTerminationByCompany celg false na duration Payment obligations under the agreement termination by the company. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false true false false 0.5 0.5 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:pureItemType pure Payment obligations under the agreement termination by the company. No authoritative reference available. false 20 Potential milestone payments 4 celg_AdditionalPaymentForEachMarketToFormerShareholdersUponApprovalOfAmrubicin celg false debit duration Additional payment for each market to the former shareholders upon approval of amrubicin. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false true false false 10000000 10000000 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Additional payment for each market to the former shareholders upon approval of amrubicin. No authoritative reference available. false 21 Potential milestone payments 4 celg_MilestonePaymentsUponRegulatoryApprovalOfAmrubicinInUnitedStates celg false credit duration Milestone payments upon regulatory approval of amrubicin in the United States. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false true false false 7000000 7000000 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Milestone payments upon regulatory approval of amrubicin in the United States. No authoritative reference available. false 22 Potential milestone payments 4 celg_MilestonePaymentsUponReceiptOfFirstApprovalInEu celg false credit duration Milestone payments upon receipt of the first approval in the E.U. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false true false false 1000000 1000000 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Milestone payments upon receipt of the first approval in the E.U. No authoritative reference available. false 23 Potential milestone payments 4 celg_MaximumMilestonePaymentsUponAchievingCertainAnnualSalesLevelsInUnitedStates celg false credit duration Maximum milestone payments upon achieving certain annual sales levels in United States. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false 17500000 17500000 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Maximum milestone payments upon achieving certain annual sales levels in United States. No authoritative reference available. false 24 Generic product units 4 celg_DifferenceUponGenericProductUnitsSoldAndNumberOfGenericProductUnitsSoldPlusLicensedProductUnitsSold celg false na duration Difference upon generic product units sold and number of generic product units sold plus licensed product units sold. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false true false false 0.2 0.2 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure Difference upon generic product units sold and number of generic product units sold plus licensed product units sold. No authoritative reference available. false 25 Potential reduction in royalty payments 4 celg_ReductionInRoyaltyPaymentObligationsUnderTerminationOfAgreement celg false na duration Reduction in royalty payment obligations under termination of agreement. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false true false false 0.5 0.5 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure Reduction in royalty payment obligations under termination of agreement. No authoritative reference available. false 26 Potential reduction in milestone payments 4 celg_ReductionInDevelopmentMilestonePaymentObligationsUnderTerminationOfAgreement celg false na duration Reduction in development milestone payment obligations under termination of agreement. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false true false false 0.5 0.5 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure Reduction in development milestone payment obligations under termination of agreement. No authoritative reference available. false 27 Research and development 4 us-gaap_ResearchAndDevelopmentExpense us-gaap true debit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false 121200000 121200000 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false true false false 4500000 4500000 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false true false false 1100000 1100000 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 false 28 Additional Collaboration Agreement Textuals [Abstract] 1 celg_AdditionalCollaborationAgreementTextualsAbstract celg false na duration Additional Collaboration Agreement Textuals Abstract false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:stringItemType string Additional Collaboration Agreement Textuals Abstract false 29 Equity investment in Agios Series B Convertible Preferred Stock 2 us-gaap_EquityMethodInvestmentAggregateCost us-gaap true debit instant No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false true false false 8800000 8800000 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary This element represents the aggregate cost of investments accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 12 -Article 5 false 30 Ownership interest 2 us-gaap_EquityMethodInvestmentOwnershipPercentage us-gaap true na instant No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false true false false 0.1094 0.1094 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false us-types:percentItemType pure The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 159 -Paragraph 18 -Subparagraph f Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 20 -Subparagraph a (1) false 31 Maximum recievable by Agios upon achievement of certain milestones 2 celg_MaximumRecievableUponAchievementOfCertainMilestones celg false debit instant Maximum recievable upon achievement of certain milestones. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false true false false 120000000 120000000 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary Maximum recievable upon achievement of certain milestones. No authoritative reference available. false 32 One time milestone payment 2 celg_OneTimeMilestonePayment celg false debit instant One time milestone payment. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 true true false false 25000000 25000000 false false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 true false false 9 false false false false 0 0 true false false 10 false false false false 0 0 true false false 11 false false false false 0 0 true false false 12 false false false false 0 0 true false false 13 false false false false 0 0 true false false 14 false false false false 0 0 true false false 15 false false false false 0 0 true false false 16 false false false false 0 0 true false false 17 false false false false 0 0 true false false 18 false false false false 0 0 true false false 19 false false false false 0 0 true false false 20 false false false false 0 0 true false false 21 false false false false 0 0 true false false 22 false false false false 0 0 true false false 23 false false false false 0 0 true false false 24 false false false false 0 0 true false false 25 false false false false 0 0 true false false 26 false false false false 0 0 true false false xbrli:monetaryItemType monetary One time milestone payment. No authoritative reference available. false 26 28 false NoRounding UnKnown UnKnown false true